Guardant Health Inc. (GH) shares plummeted 10.25% in intraday trading on Thursday, surprising investors given the company's strong second-quarter results and raised full-year guidance. The precision oncology company's stock performance contradicted the positive news surrounding its financial achievements and analyst upgrades.

Guardant Health reported impressive Q2 2025 results, with revenue soaring 31% year-over-year to $232.1 million, beating analyst estimates by $20.6 million. The company's non-GAAP earnings per share also improved to ($0.44), surpassing expectations of ($0.73). Furthermore, Guardant Health raised its full-year 2025 revenue guidance to $915–$925 million, reflecting continued strong momentum in its Shield and core oncology products.

Despite these positive developments, investors seemed to focus on other factors not immediately apparent in the earnings report. The stock's significant drop suggests concerns about the company's ongoing cash burn, competitive pressures in the precision oncology market, or broader market volatility affecting growth stocks. As trading continued throughout the day, Guardant Health's stock decline worsened, with the company's shares down 7.0% in a volume spike by mid-afternoon. This disconnected market reaction highlights the complexity of factors influencing stock performance beyond headline financial results.